Markets

Infection treatment biotech Ruthigen files for a $27 million IPO

Ruthigen, a biotech developing therapeutics to prevent and treat infection in surgical and trauma procedures, filed on Thursday with the SEC to raise up to $27 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol RTGN. Ruthigen initially filed confidentially on May 24, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos